Please login to the form below

Not currently logged in
Email:
Password:

Trial success for Novartis' psoriasis drug

Novartis has presented data at the European Academy of Dermatology and Venereology Congress that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 per cent of patients

Novartis has presented data at the European Academy of Dermatology and Venereology (EADV) Congress in Lisbon, Portugal, that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 per cent of patients.

The company said one phase II study showed 81 per cent of patients receiving AIN457 150mg subcutaneously once a month experienced at least a 75 per cent improvement of psoriasis signs and symptoms.

A separate study demonstrated 83 per cent of patients who were given an intravenous starting dose of AIN457 experienced at least a 75 per cent improvement of symptoms. This compared to 10 per cent of patients on placebo.

The treatment, a fully human monoclonal antibody neutralizing interleukin-17A that may provide a new mechanism of action for the treatment of immune-mediated diseases, was also shown to be more effective when used early on in the therapeutic process.

Dr Kim Papp, dermatologist and director of research at Probity Medical Research, Waterloo, Ontario, Canada, said the results suggest that AIN457 could bring "considerable improvement" to the lives of patients with psoriasis, and emphasised the fast-acting action of the drug.

John Hohneker, global head of development for Integrated Hospital Care at Novartis, said: "We are encouraged by these positive phase II results and look forward to receiving the results of larger-scale and longer-term phase III studies with AIN457 which began this year."

24th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics